5 news items
Sage Therapeutics to Participate in Upcoming May Investor Conferences
SAGE
7 May 24
Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
SAGE
25 Apr 24
(NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
SAGE
17 Apr 24
(NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
SAGE
11 Apr 24
(NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver
Sage Therapeutics to Present at Upcoming March Investor Conferences
SAGE
28 Feb 24
Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed
- Prev
- 1
- Next